Inhibikase Therapeutics (IKT) Non-Current Assets (2021 - 2026)

Inhibikase Therapeutics (IKT) has 6 years of Non-Current Assets data on file, last reported at $1.2 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $1.2 million, up 891.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 million (up 398.23% YoY), and the FY2025 annual result was $1.1 million, up 637.27% from the prior year.
• Non-Current Assets improved to $1.2 million in Q1 2026 per IKT's latest filing, from $1.1 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $1.2 million in Q1 2026 and troughed at $43089.0 in Q2 2022.
• A 5-year average of $439413.5 and a median of $312814.5 in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2025 and 2026: Non-Current Assets tumbled 73.84% in 2025, then surged 891.52% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $565175.0 in 2022, then slumped by 47.7% to $295599.0 in 2023, then sank by 49.75% to $148537.0 in 2024, then soared by 637.27% to $1.1 million in 2025, then gained by 5.54% to $1.2 million in 2026.
• Business Quant data shows IKT's Non-Current Assets at $1.2 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.